Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Short-course versus long-course antibiotic treatment in patients with uncomplicated gram-negative bacteremia: A systematic review and meta-analysis.Journal of clinical pharmacy and therapeutics · 2021Pooled it
- Managing multidrug resistant Gram-negative bacteraemia in immunocompromised hosts.Current opinion in infectious diseases · 2026Review
- A temperate phage encoding a catalytically active endolysin: characterization of phage P7869 and its Lys7869 against Pseudomonas aeruginosa.BMC microbiology · 2026Article
- Genomic Epidemiology and Antimicrobial Resistance Analyses ofInfection and drug resistance · 2026Article
- Antibiotic therapy for severe bacterial infections.Intensive care medicine · 2025Review
- Review
- Standardization in the management of gram-negative bloodstream infections after implementation of a clinical care guideline at a large academic, safety-net institution: a quasi-experimental study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Is Short-Course Antibiotic Therapy Suitable for Pseudomonas aeruginosa Bloodstream Infections in Onco-hematology Patients With Febrile Neutropenia? Results of a Multi-institutional Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Relationship between Target Time above Minimum Inhibitory Concentration Achievement Rate of Meropenem Using Monte Carlo Simulation and In-Hospital Survival in Patients withAntibiotics (Basel, Switzerland) · 2024Article
- Risk factors for positive follow-up blood cultures in Gram-negative bacteremia among immunocompromised patients with neutropenia.Transplant infectious disease : an official journal of the Transplantation Society · 2024Article
- Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream Infections.JAMA network open · 2024Article
- Bring it on again: antimicrobial stewardship in transplant infectious diseases: updates and new challenges.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Review
- Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action.World journal of emergency surgery : WJES · 2023Review
- Uncovering the Resistance Mechanisms in Extended-Drug-ResistantMicroorganisms · 2023Article
- Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Anti-Microorganisms · 2023Review
- Antimicrobial Therapy Duration for Bloodstream Infections Caused byAntibiotics (Basel, Switzerland) · 2023Article
- Accurate, Sensitive, and Rapid Detection of Pseudomonas aeruginosa Based on CRISPR/Cas12b with One Fluid-Handling Step.Microbiology spectrum · 2023Article
- Review
- Duration of antibiotic treatment for Gram-negative bacteremia - Systematic review and individual participant data (IPD) meta-analysis.EClinicalMedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
In a multicenter, observational, propensity-score-weighted cohort of 249 adults with uncomplicated Pseudomonas aeruginosa bacteremia, patients receiving short-course (median, 9 days; interquartile range [IQR], 8-10) therapy had a similar odds of recurrent infection or death within 30 days as those receiving longer courses (median, 16 days; IQR, 14-17).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.